Why CASI Pharmaceuticals Is Crashing Today

1 min read

CASI Pharmaceuticals (NASDAQ: CASI) was down by roughly 15% in late trading on Wednesday, against the more or less flat performance of the S&P 500 index. The catalyst is the company’s pricing of a relatively large and dilutive public issue of new stock.

CASI announced Wednesday morning that it is issuing just under 15.9 million shares of its common stock at a price of $2.05 per share. The issue’s underwriters have also collectively been granted an option to buy nearly 2.4 million additional shares.

Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Enerpac Tool Group (EPAC) Q2 2021 Earnings Call Transcript

Next Story

Why BioNTech Stock Sank Today

Latest from Blog